These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 35892475)
1. Modelling the Cost-Effectiveness and Budget Impact of a Newborn Screening Program for Spinal Muscular Atrophy and Severe Combined Immunodeficiency. Shih STF; Keller E; Wiley V; Farrar MA; Wong M; Chambers GM Int J Neonatal Screen; 2022 Jul; 8(3):. PubMed ID: 35892475 [TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation of Newborn Screening for Severe Combined Immunodeficiency. Shih STF; Keller E; Wiley V; Wong M; Farrar MA; Chambers GM Int J Neonatal Screen; 2022 Jul; 8(3):. PubMed ID: 35892474 [TBL] [Abstract][Full Text] [Related]
3. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. Shih ST; Farrar MA; Wiley V; Chambers G J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1296-1304. PubMed ID: 34321343 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands. Velikanova R; van der Schans S; Bischof M; van Olden RW; Postma M; Boersma C Value Health; 2022 Oct; 25(10):1696-1704. PubMed ID: 35963838 [TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England. Weidlich D; Servais L; Kausar I; Howells R; Bischof M Neurol Ther; 2023 Aug; 12(4):1205-1220. PubMed ID: 37222861 [TBL] [Abstract][Full Text] [Related]
6. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487 [TBL] [Abstract][Full Text] [Related]
7. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Chan K; Davis J; Pai SY; Bonilla FA; Puck JM; Apkon M Mol Genet Metab; 2011 Nov; 104(3):383-9. PubMed ID: 21810544 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in Italy. Ghetti G; Mennini FS; Marcellusi A; Bischof M; Pistillo GM; Pane M Clin Drug Investig; 2024 Sep; 44(9):687-701. PubMed ID: 39172297 [TBL] [Abstract][Full Text] [Related]
9. The case for severe combined immunodeficiency (SCID) and T cell lymphopenia newborn screening: saving lives…one at a time. Quinn J; Orange JS; Modell V; Modell F Immunol Res; 2020 Feb; 68(1):48-53. PubMed ID: 32128663 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of newborn screening for severe combined immunodeficiency. Van der Ploeg CPB; Blom M; Bredius RGM; van der Burg M; Schielen PCJI; Verkerk PH; Van den Akker-van Marle ME Eur J Pediatr; 2019 May; 178(5):721-729. PubMed ID: 30805731 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand. Phisalprapa P; Supakankunti S; Chaiyakunapruk N J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247 [No Abstract] [Full Text] [Related]
12. A Cost-Effectiveness Analysis of Newborn Screening for Severe Combined Immunodeficiency in the UK. Bessey A; Chilcott J; Leaviss J; de la Cruz C; Wong R Int J Neonatal Screen; 2019 Sep; 5(3):28. PubMed ID: 33072987 [TBL] [Abstract][Full Text] [Related]
13. Societal value of newborn screening for severe combined immune deficiency in Arkansas: An economic analysis. Hays LH Public Health Nurs; 2019 Jul; 36(4):541-544. PubMed ID: 30945355 [TBL] [Abstract][Full Text] [Related]
14. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy]. Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779 [TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy. Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229 [TBL] [Abstract][Full Text] [Related]
16. Potential costs and benefits of newborn screening for severe combined immunodeficiency. McGhee SA; Stiehm ER; McCabe ER J Pediatr; 2005 Nov; 147(5):603-8. PubMed ID: 16291349 [TBL] [Abstract][Full Text] [Related]
17. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment. Health Quality Ontario Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251 [TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India's Current Family Welfare Programme. Joshi B; Moray KV; Sachin O; Chaurasia H; Begum S Appl Health Econ Health Policy; 2021 Mar; 19(2):267-277. PubMed ID: 32776166 [TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden. Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083 [TBL] [Abstract][Full Text] [Related]